Journal of Medical Biochemistry最新文献

{"title":"Biochemical impact and therapeutic efficacy of laparoscopic surgery in early-stage ovarian cancer: Modulation of vascular endothelial growth factor and tumor markers.","authors":"Peng Han, Yafei Liu, Jin Han","doi":"10.5937/jomb0-56011","DOIUrl":"10.5937/jomb0-56011","url":null,"abstract":"<p><strong>Background: </strong>The objective of this study was to investigate the biochemical impact of laparoscopic surgery on angiogenesis, focusing on vascular endothelial growth factor (VEGF), and the modulation of key tumor markers in patients with early-stage ovarian cancer.</p><p><strong>Methods: </strong>A total of 76 patients diagnosed with early ovarian cancer were enrolled and divided into two groups based on the surgical approach: the control group (n=38) underwent open surgery, and the observation group (n=38) underwent laparoscopic surgery. Surgical parameters, VEGF levels, tumor markers [matrix metalloproteinase 9 (MMP9), stromal cell-derived factor-1a (SDF-1a), and carcinoembryonic antigen (CEA)], survival rates, and incidence of complications were compared between the two groups.</p><p><strong>Results: </strong>The duration of surgery was longer in the observation group than in the control group. However, the hospitalization time, recovery of bowel function, and length of surgical incision were significantly shorter in the observation group. Intraoperative blood loss was also significantly lower in the observation group, with all differences being statistically significant (P<0.01). Seven days post-surgery, VEGF, MMP9, SDF-1a, and CEA levels in both groups decreased compared to their preoperative levels. These levels were significantly lower in the observation group than in the control group (P<0.05). The 24-month survival rate was higher in the observation group (P<0.05). There was no statistically significant difference in the total incidence of complications between the two groups (P>0.05).</p><p><strong>Conclusions: </strong>Laparoscopic surgery for early ovarian cancer results in minimal trauma, reduces VEGF and tumor marker levels, and improves the 24-month survival rate without increasing the incidence of complications.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 3","pages":"432-437"},"PeriodicalIF":1.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risk in patients with a relationship with oxidative stress and dyslipidemia.","authors":"Vesna Karanikolic, Mirjana Bakic, Sanja Gluscevic, Filiz Mercantepe, Aleksandra Klisic","doi":"10.5937/jomb0-52038","DOIUrl":"10.5937/jomb0-52038","url":null,"abstract":"<p><strong>Background: </strong>Patients with psoriasis are at an increased risk of cardiovascular disease (CVD). Psoriasis and atherosclerosis share the common soil of inflammation and oxidative stress in their pathogenesis. The current study aimed to examine cardiovascular risk concerning some non-traditional (i.e., biomarkers of oxidative stress and inflammation) and traditional metabolic parameters in patients with psoriasis.</p><p><strong>Methods: </strong>A total of 68 (57% men) patients with psoriasis were included. Traditional metabolic parameters, markers of oxidative stress[i.e., oxidation protein products (AOPP), malondialdehyde (MDA), catalase (CAT), and superoxide dismutase (SOD)] and inflammation (C-reactive protein) were measured. The atherosclerotic cardiovascular disease (ASCVD) risk score was used to measure CVD risk. Patients were divided into ASCVD score tertiles.</p><p><strong>Results: </strong>Patients with a higher ASCVD score had significantly lower high-density lipoprotein cholesterol (HDL-C), higher triglycerides (TG), and higher TG/HDL-C ratio (p for trend p<0.001). Among redox status parameters, only AOPP showed a significant increase in parallel with the ASCVD score increase (p=0.011). In univariate binary logistic regression analysis, AOPP [OR, 95% CI=1.027 (1.004-1.051), p=0.021] and TG [OR, 95% CI =7.220 (2.041-25.548), p=0.002] correlated with the ASCVD risk score. In multivariate analysis (backward method), only TG was an independent predictor of ASCVD score [OR, 95%CI =7.220 (2.041-25.548), p=0.002].</p><p><strong>Conclusions: </strong>The results show the association between ASCVD score and oxidative stress (AOPP) and dyslipidemia (TG), respectively, in patients with psoriasis, but only TG retained its independent association with ASCVD risk score. Measuring serum TG levels is very important in patients with increased ASCVD risk concerning psoriasis.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 3","pages":"614-621"},"PeriodicalIF":1.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and biochemical efficacy zoledronic acid and denosumab combination: focus serum inflammatory factor level (serum ifcs), bone gla protein (bgp), and bone turnover markers b-collagen degradation product (b-ctx), and procollagen type 1 n-terminal propeptide (p1np).","authors":"Lingyan Kong, Jun Ma","doi":"10.5937/jomb0-51444","DOIUrl":"10.5937/jomb0-51444","url":null,"abstract":"<p><strong>Background: </strong>Postmenopausal osteoporosis (PMOP) is a prevalent metabolic bone disorder characterized by decreased bone mineral density (BMD) and skeletal fragility, leading to increased susceptibility to fractures. The therapeutic efficacy of zoledronic acid and denosumab, two widely used agents in the treatment of osteoporosis, was investigated in this study. The primary objective was to evaluate the clinical effects of zoledronic acid and denosumab on serum inflammatory cytokine (IFC) levels and BMD in PMOP patients.</p><p><strong>Methods: </strong>A prospective, non-blinded, randomized controlled trial was conducted at our hospital from March 2021 to March 2024. Eighty PMOP patients were recruited and randomly assigned to either a control group (CG, n=40) or a treatment group (TG, n=40). The CG received zoledronic acid plus traditional treatment, while the TG received zoledronic acid plus denosumab plus traditional treatment. Clinical symptom improvement and changes in BMD were assessed and compared between the two groups. Serum IFC levels, including bone Gla protein (BGP) and bone turnover markers b-collagen degradation product (b-CTX) and procollagen type 1 N-terminal propeptide (P1NP), were measured.</p><p><strong>Results: </strong>Compared to the CG, patients in the TG demonstrated significantly increased BMD (P<0.05) and decreased levels of serum IFCs, BGP, and bone turnover markers (P<0.05). Additionally, the incidence of adverse reactions was significantly lower (P<0.05) in the TG, and the total effective rate of clinical treatment was significantly higher (P<0.05).</p><p><strong>Conclusions: </strong>The combination of zoledronic acid and denosumab exhibited improved clinical efficacy in PMOP patients, as evidenced by enhanced BMD and reduced serum IFC levels. These findings suggest that this combined treatment regimen may promote the treatment of osteoporosis by suppressing inflammatory responses, thereby providing a novel therapeutic approach for the management of PMOP.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 3","pages":"587-594"},"PeriodicalIF":1.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PCSK9 inhibitors reduces arterial stiffness in patients with acute coronary syndrome.","authors":"Liang Wang, Ruijie Wang, Tiantian Jiao, Linghao Xu, Endong Ji, Yuanzhen Jiang, Yuanqi Wang, Yehong Liu, Jiming Li","doi":"10.5937/jomb0-54773","DOIUrl":"10.5937/jomb0-54773","url":null,"abstract":"<p><strong>Background: </strong>This study focuses on uncovering the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in attenuating arterial stiffness in patients with acute coronary syndrome (ACS) and atherosclerosis.</p><p><strong>Methods: </strong>A total of 71 ACS patients were enrolled in this study from April 1, 2022, to June 31, 2022. Patients were randomly assigned to two groups: one group received statin therapy combined with PCSK9 inhibitors (Evolocumab 140 mg or Alirocumab 75 mg every two weeks) (n = 36), and the other group received statins alone (n = 35). All patients underwent measurements of lipid metabolism and arterial stiffness at baseline, 1 month, and 6 months after treatment initiation. Statistical power analysis indicated that the sample size of 71 patients provided sufficient power to detect significant differences.</p><p><strong>Results: </strong>After 1 month, the group treated with statins and PCSK9 inhibitors showed significantly greater reductions in total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and lipoprotein(a) [Lp(a)] levels compared to the statin-only group (p = 0.027 and p = 0.021, respectively). By the 6-month follow-up, significant reductions were observed in pulse wave velocity (PWV) and ankle-brachial index (ABI) in the combination treatment group (p < 0.05). However, no significant differences were observed between Evolocumab and Alirocumab in terms of arterial stiffness improvement (p > 0.05). Statistical power was sufficient to detect these changes.</p><p><strong>Conclusions: </strong>The findings suggest that PCSK9 inhibitors, when combined with statins, not only improve lipid metabolism but also reduce arterial stiffness, offering potential benefits for vascular health in patients with ACS and atherosclerosis. Further studies with larger sample sizes and longer follow-up periods are necessary to confirm these results.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 3","pages":"412-421"},"PeriodicalIF":1.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of serum tumor markers (carcinoembryonic antigen, neuron-specific enolase, and squamous cell carcinoma antigen in non-small cell lung cancer patients treated with programmed cell death protein 1 inhibitors.","authors":"Yang Wang, Danqing Li","doi":"10.5937/jomb0-54181","DOIUrl":"10.5937/jomb0-54181","url":null,"abstract":"<p><strong>Background: </strong>Adverse reactions (ARs) may occur in patients with advanced non-small cell lung cancer (ANSCLC) undergoing treatment with programmed cell death protein 1 (PD-1) inhibitors (PD-1Is). Establishing a risk assessment model can facilitate personalized treatment.</p><p><strong>Methods: </strong>Clinical data were collected from 215 ANSCLC patients treated with PD-1Is. Patients who experienced ARs were classified as the observation group (OG, 92 cases), while those who did not experience ARs were classified as the control group (CG, 123 cases). A multivariable logistic regression (LR) model was employed to analyze independent risk factors (RFs) associated with ARs, and R Studio software was utilized to create a nomogram predictive model.</p><p><strong>Results: </strong>The concordance index for the nomogram predictive model for ARs in ANSCLC patients treated with PD-1Is was 0.911. The threshold for predicting ARs using the nomogram was more significant than 0.25, providing a clinical net benefit superior to individual indicators such as smoking, tumour-node-metastasis (TNM) staging, neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI). The proportion of smokers in the OG was markedly superior to that in the CG (P<0.05).</p><p><strong>Conclusions: </strong>Smoking, TNM staging, and peripheral blood indicators such as NLR, SII, and PNI are independent RFs for the occurrence of ARs. The constructed nomogram predictive model demonstrates greater clinical utility than individual indicators, enhancing the accuracy of AR predictions.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 3","pages":"678-686"},"PeriodicalIF":1.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357619/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Traditional Chinese medicine as an adjunctive therapy improves cardiac function and reduces serum inflammatory markers in patients with chronic heart failure.","authors":"Yonghong Zheng, Chunhui Huang, Wei Zhang, Yiping Shi, Fangchao Chen, Jianru Zhou","doi":"10.5937/jomb0-54440","DOIUrl":"10.5937/jomb0-54440","url":null,"abstract":"<p><strong>Background: </strong>To evaluate the impact of traditional Chinese medicine treatment versus standard treatment on cardiac function metrics, serum inflammatory markers, and quality of life in patients with chronic heart failure (CHF).</p><p><strong>Methods: </strong>A total of 40 CHF patients were randomly assigned to either the observation group (TCM treatment) or the control group (standard Western therapy), with 20 patients in each group. Over a 3-month treatment period, primary outcomes including cardiac function indicators (ejection fraction [EF], cardiac output [CO], left ventricular end-diastolic pressure [LVEDP]), exercise tolerance (6-minute walk test [6MWT] results), and inflammatory markers (high-sensitivity C-reactive protein [hs-CRP], interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-a]) were assessed. Secondary outcomes included the Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores and adverse reaction rates. Statistical analysis was performed using t-tests and chi-square tests, with significance set at P < 0.05.</p><p><strong>Results: </strong>After treatment, the observation group showed significantly greater improvements in EF (44.14% ± 4.95% vs. 40.15% ± 4.77%, P = 0.013), CO (4.62 ± 0.76 L/min vs. 4.10 ± 0.72 L/min, P = 0.032), LVEDP (18.76 ± 2.50 mmHg vs. 20.80 ± 2.64 mmHg, P = 0.016), and 6MWT results (526.84 ± 49.20 m vs. 432.75 ± 37.26 m, P < 0.001), compared to the control group. Inflammatory markers and MLHFQ scores were also significantly improved, while the adverse reaction rate was lower in the observation group (0.00% vs. 20.00%, P = 0.035).</p><p><strong>Conclusions: </strong>TCM as an adjunctive therapy demonstrates superior efficacy and safety compared to standard treatment for CHF, with significant improvements in cardiac function, exercise tolerance, and inflammatory markers. These findings provide quantitative evidence supporting the clinical application of TCM in CHF management.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 3","pages":"507-514"},"PeriodicalIF":1.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357615/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunophenotypic characteristics and prognostic value of peripheral blood circulating plasma cells in patients with newly diagnosed multiple myeloma.","authors":"Hong Chen, Yuan Zhao, Zhiyu Zhang, Yan Xie, Mulan Jin","doi":"10.5937/jomb0-55319","DOIUrl":"10.5937/jomb0-55319","url":null,"abstract":"<p><strong>Background: </strong>To investigate the immunophenotypic characteristics and prognostic value of peripheral blood circulating plasma cells (CPCs) in patients with newly diagnosed multiple myeloma (NDMM).</p><p><strong>Methods: </strong>This retrospective study was conducted on NDMM patients treated at Beijing Chaoyang Hospital, Capital Medical University, between January 2020 and June 2023. A total of 57 patients were included, with a median age of 64 years, comprising 27 males. Forty-four patients were assigned to the higher CPCs group and 13 to the lower CPCs group. To compare the proportion of bone marrow plasma cells (BMPCs) between the two groups and to analyse the differences in the immunophenotypes of BMPCs and CPCs. Subsequently, the prognosis of the patients was analysed by COX.</p><p><strong>Results: </strong>The percentage of BMPCs was significantly higher in the higher CPCs group compared to the lower CPCs group (53.07% vs. 15.23%, P<0.001). In the higher CPCs group, BMPCs exhibited decreased expression of CD56 and CD27 but increased expression of CD81 (all P<0.05). The median PFS in the lower CPCs group (17.6 months, 9.12-31.54) was significantly higher than that in the higher CPCs group (14.1 months, 5.08-26.12) (P=0.015). Multivariate Cox regression analysis identified CPCs ≥ 0.0101% (HR=6.721, 95% CI: 3.891-11.224, P<0.001) as the independent prognostic factors for PFS.</p><p><strong>Conclusions: </strong>This study demonstrates distinct immunophenotypic differences between the higher and lower CPCs groups in NDMM patients.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 3","pages":"668-677"},"PeriodicalIF":1.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of puerarin administration on serum NOD-like receptor protein 3 (NLRP3) inflammasome, C1Q/TNF-related protein 3 (CTRP3) and lipoprotein-associated phospholipase 2 (LP-PLA2) levels.","authors":"Ge Wang, Qisheng Tang, Dan Wang","doi":"10.5937/jomb0-53546","DOIUrl":"10.5937/jomb0-53546","url":null,"abstract":"<p><strong>Background: </strong>Coronary heart disease (CHD) is a cardiovascular disease with a high incidence in elderly patients. This article aimed to evaluate the clinical efficacy of puerarin (Pue) as an adjuvant therapy in elderly patients with CHD and the effects of Pue on serum NOD-like receptor protein 3 (NLRP3) inflammasome, C1q/TNF-Related Protein 3 (CTRP3) and lipoprotein-associated phospholipase 2 (Lp-PLA2) levels.</p><p><strong>Methods: </strong>This retrospective cohort study compared two treatment approaches for CHD patients at Beijing University of Chinese Medicine Third Affiliated Hospital. Fifty-nine patients received standard treatment (5% glucose + nitroglycerin), and 59 received a new treatment (5% glucose + Pue injection). Outcomes were assessed using electrocardiograms, laboratory tests, and cardiac function evaluations.</p><p><strong>Results: </strong>Relative to the controls, the study subjects had a reduction in the number of angina episodes and an increase in exercise tolerance. In addition, the serum NLRP3 inflammasome and Lp-PLA2 distinctly decreased, and the serum CTRP3 distinctly increased in study subjects.</p><p><strong>Conclusions: </strong>The administration of puerarin as an adjuvant therapy in elderly patients with coronary heart disease demonstrated significant clinical efficacy, as evidenced by reduced angina episodes and improved exercise tolerance; this might be driven through inflammatory and lipid metabolism pathways.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 3","pages":"561-567"},"PeriodicalIF":1.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12358014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Altered levels of sphingolipid metabolites in serum of locally advanced rectal cancer patients: A pilot study.","authors":"Jasna Bjelanović, Aleksandra Nikolić, Mutay Aslan, Marko Miladinov, Nikola Kotur, Goran Barišić, Sandra Dragicević","doi":"10.5937/jomb0-55113","DOIUrl":"10.5937/jomb0-55113","url":null,"abstract":"<p><strong>Background: </strong>Altered sphingolipid levels might contribute to rectal cancer development, progression and therapy response by regulating various biological processes, including apoptosis. This study aimed to analyse the serum sphingolipid profile in rectal cancer patients and investigate its association with the apoptotic status of tumour tissue and therapy response.</p><p><strong>Methods: </strong>Ceramide (CER) and sphingomyelin (SM) serum levels were analysed in 22 patients with locally advanced rectal cancer and 24 healthy individuals by ultrafast liquid chromatography coupled with tandem mass spectrometry. The expression of pro-apoptotic BAX (BCL2 associated X, apoptosis regulator) and anti-apoptotic BCL2 (BCL2 apoptosis regulator) was analysed in tumour and corresponding healthy tissue samples of patients by quantitative real-time PCR.</p><p><strong>Results: </strong>Significantly lower serum levels of C18 CER, C22 CER, C24 CER, C18 SM and C24 SM were observed in patients than in controls (P<0.05). For C20 CER, C22 CER and C24 CER, a positive correlation with the pro-apoptotic status of tumour tissue was found (r=0.619, P=0.018; r=0.694, P=0.006 and r=0.601, P=0.023, respectively). No difference in serum sphingolipid levels was found between patients with good, moderate, and poor responses to therapy.</p><p><strong>Conclusions: </strong>These results support the involvement of sphingolipids in rectal cancer. However, further studies, including a larger cohort of subjects, are needed to clarify the association of sphingolipid metabolites with therapy response.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 3","pages":"524-533"},"PeriodicalIF":1.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the effects of transthoracic echocardiography and transesophageal echocardiography on stress injury, pain mediators in patients with severe aortic stenosis.","authors":"Aidong Chen, Bin Chen, Po Yang, Xiaoming Shi, Zhipeng Xu, Fanxin Deng","doi":"10.5937/jomb0-55774","DOIUrl":"10.5937/jomb0-55774","url":null,"abstract":"<p><strong>Background: </strong>We compared the differences in the effects of transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) on hemodynamics, inflammatory stress response, and pain mediators in patients with severe aortic stenosis (AS).</p><p><strong>Methods: </strong>204 patients with severe AS treated with transcatheter aortic valve replacement (TAVR) in our hospital were selected as the research subjects from January 2022 to February 2024. Among them, 109 patients received TTE (TTE group), and another 95 received TEE (TEE group). Differences in the evaluation effects of preoperative echocardiography and multi-slice helical computed tomography (MSCT) in all patients were compared, and changes in echocardiographic parameters before and after surgery were observed. In addition, the differences in postoperative hemodynamics, cardiac function [brain natriuretic peptide (BNP), cardiac troponin I (cTnI), creatine kinase isoenzyme (CK-MB)], stress response [superoxide dismutase (SOD), malondialdehyde (MDA)], inflammatory factors [Interleukin-1b/6 (IL-1b/6), tumour necrosis factor-a (TNF-a)], and pain mediators [5-hydroxytryptamine (5-HT), endothelin-1 (ET-1), prostaglandin E2 (PGE2), substance P (SP)] between the observation and TTE groups were compared.</p><p><strong>Results: </strong>No differences were identified in the evaluation of the aortic root between echocardiography and MSCT (P>0.05). After surgery, parameters such as LVESD and IVST decreased, while LVEF and AVA increased (P<0.05). The TEE group showed superior postoperative hemodynamics to the TTE group (P<0.05). There was no difference in cardiac function between the two groups (P>0.05), but IL-1b, IL-6, TNF-a, 5-HT, ET-1 and SP were lower in the TEE group than in the TTE group, whereas SOD was higher than in the TTE group (P<0.05).</p><p><strong>Conclusions: </strong>TTE and TEE have an excellent guiding effect on the implementation of TAVR in patients with severe AS, among which TEE is more helpful in improving the effectiveness and safety of TAVR.</p>","PeriodicalId":16175,"journal":{"name":"Journal of Medical Biochemistry","volume":"44 3","pages":"660-667"},"PeriodicalIF":1.5,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}